Belantamab mafodotin
- Generic Name
- Belantamab mafodotin
- Brand Names
- BLENREP
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2050232-20-5
- Unique Ingredient Identifier
- DB1041CXDG
- Background
Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF).
Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma; however, its manufacturer began the process for withdrawal of the US marketing authorization in November 2022. In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program.
- Indication
Belantamab mafodotin is indicated in the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
Cancer Antibody Drug Conjugates Market, Drugs Approval & Clinical Trials Report 2024
The Cancer Antibody Drug Conjugates Market report highlights the transformative potential of ADCs in cancer treatment, with 16 approved products and sales exceeding $10B in 2023. The market is projected to surpass $50B by 2030, driven by ongoing clinical trials and increased R&D efforts. Key players include Padcev, Kadcyla, and Enhertu, with significant development activity in lung and breast cancer. The market is led by the US and China, with major pharmaceutical companies driving innovation.
Alarm bell rings for GSK as US policy dents RSV jab sales
GSK's RSV vaccine Arexvy sales dropped 72% in Q3 due to narrower US recommendations and COVID-19 vaccination prioritization. Pfizer's Abrysvo sales declined only 5%, suggesting Pfizer's ascendency in the RSV vaccine market. GSK's overall vaccine sales fell 15%, leading to a revised forecast of low-single-digit percentage gains. Despite this, GSK's overall revenues increased 2% to $8 billion, supported by HIV drugs and specialty medicines.
GSK on track to deliver 2024 outlooks with further good progress made in R&D
GSK delivered Q3 sales and core operating profit growth, with strong specialty medicines offsetting lower vaccine sales. The pipeline strengthened with 11 positive phase III trials and 5 major product launches planned for next year. Zantac litigation was resolved, aligning with 2024 guidance and bolstering confidence in 2026 and 2031 outlooks. Forward-looking statements are subject to risks and uncertainties.
GSK Plc confirms 2024 guidance; Q3 dividend of 15p declared
GSK Q3 2024 results: £8.0 billion sales (-2% AER, +2% CER), driven by Specialty Medicines (+19%) offsetting Vaccines (-15%). Core operating profit +5%, Core EPS +5%. R&D progress includes EU approval for Arexvy, HIV PrEP effectiveness, and oncology breakthroughs. 2024 guidance confirmed: 7-9% turnover growth, 11-13% Core operating profit growth, 10-12% Core EPS growth, excluding COVID-19 solutions.
The Targeted Pulse: Uncover Essential Developments in Breast Cancer, Multiple Myeloma
FDA approves Cologuard Plus for colorectal cancer screening; advancements in breast cancer care include genomic testing; HBI0101 CAR T-cell therapy shows promise in multiple myeloma; neoadjuvant nivolumab plus chemotherapy approved for NSCLC; Belantamab mafodotin-blmf combo demonstrates efficacy in relapsed/refractory multiple myeloma.
Related Clinical Trials:
EU regulators recommend against renewing approval for GSK's Blenrep
The article discusses the importance of summarizing content accurately and concisely, focusing on core information without explanatory sentences.
BPd Maintains QOL vs PVd, Supporting Its Use as a New SOC in R/R Myeloma
DREAMM-8 trial showed BPd (belantamab mafodotin-blmf, pomalidomide, dexamethasone) was generally well-tolerated and maintained HR-QOL over time in relapsed/refractory multiple myeloma patients compared to PVd (bortezomib, pomalidomide, dexamethasone). BPd led to more significant improvements in physical functioning and fatigue, supporting its potential as a new standard of care.
Belantamab Mafodotin Plus VRd Demonstrates Efficacy in Newly Diagnosed, Transplant
The GEM-BELA-VRD trial showed 94% ORR with belantamab mafodotin-blmf, bortezomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma patients, with CR rates improving from 36% to 82% over treatment phases. MRD-negative rates increased from 60.9% to 91.2%. High-risk patients achieved 100% MRD-negative status post-consolidation. PFS rates were 90% at 12 months and 85% at 24 months, with OS rates of 92% and 85% respectively. Ocular toxicity was the main adverse effect, with manageable outcomes.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath